Our siRNA coagulation disorders portfolio is developing therapeutic options that address significant challenges associated with current standard of care antithrombotics: Direct Oral Anticoagulants (DOACs). DOACs like Eliquis (apixaban), the second best-selling drug globally with more than US$20 billion annual sales in 2024, and other billion-dollar drugs in this class represent the current standard of treatment in most anticoagulation indications. However, they still present limitations such as bleeding risk and the need for daily dosing that our investigational therapies are designed to overcome. Our Core Product, SRSD107, is a novel Factor XI (FXI) siRNA that provides a differentiated profile by combining potential bleeding safety, dosing frequency, longer acting effect and the potential to treat high-risk patient populations currently non-eligible for DOACs and patients under DOAC treatments but need dose adjustments. SRSD107 could address the bleeding risk, drug-drug interactions, renal impairment, and poor patient adherence challenges.
Anchored by SRSD107, we are seeking to build a synergistic pipeline designed to address thrombosis through a multi-asset strategy. This includes novel anticoagulant focused on enhanced efficacy for patients at high risk for thrombosis, while offering a superior safety profile. Together, these efforts are positioned to address the limitations of current stand of coagulation care, offering novel solutions across the spectrum of thrombosis and hemostasis
Our cardiometabolic franchise is poised to transform cardiometabolic disease care, dedicated to addressing genetically defined drivers of disease with high unmet medical need. At the forefront of this franchise is SRSD216, a differentiated, GalNAc-conjugated siRNA therapeutic candidate designed to potently and sustainably lower Lp(a).
Beyond SRSD216, we are building a deep and synergistic pipeline to address the broad spectrum of cardiometabolic drivers. This includes multiple programs addressing dyslipidemia, metabolic diseases, and cardiovascular conditions. Our portfolio features several research programs targeting adipose and liver tissues for cardiometabolic benefits, including lipid and triglyceride management, and diabetes; and research programs for the treatment of heart failure, enabled by extrahepatic delivery technologies that engage cardiac tissue. These programs are designed with complementary mechanisms in mind, offering the potential for combinations to achieve additive or synergistic benefits across multiple cardiometabolic and cardiovascular pathways. This multi-asset strategy ensures we are well-positioned to offer a portfolio of transformative, convenient therapies for a range of high-risk patient populations and solidify our leadership in novel cardiometabolic care.
The obesity treatment landscape is dominated by the multi-billion dollar GLP-1 receptor agonists, which, despite their transformative efficacy, face significant limitations including gastrointestinal toxicity, diminishing weight loss effects over time, suboptimal efficacy in certain populations, substantial loss of lean muscle mass, and high discontinuation rates (50-68%). Approximately 25% of all patients are intolerant to GLP-1 therapy due to side effects. These limitations create substantial unmet medical needs in long-term weight management. Our obesity franchise is investigating a portfolio of at least five siRNA assets, including SRSD384, specifically engineered to overcome these limitations.
Sirius Therapeutics, Inc., all rights reserved
为了更好的呈现效果，移动端请竖屏浏览
